Blackstone Commits $455 Million to Co-Fund Boston Scientific’s Vitalyst Heart Pump

Key figures: Blackstone Life Sciences co-funding up to $455 million · First Boston Scientific–BXLS co-development deal · Aiming toward a 2030 commercial launch · Temporary pVAD market projected above $3 billion by 2035 (company estimate)

Blackstone Life Sciences will put up to $455 million behind development of Boston Scientific’s Vitalyst miniature heart pump, according to a Blackstone announcement dated Nov. 2, 2026. The Cambridge, Massachusetts–based investment platform said the money will co-fund the Vitalyst Temporary Percutaneous Transvalvular Circulatory Support System, a next-generation pump intended for patients in acute myocardial infarction cardiogenic shock. It is the first time Blackstone Life Sciences and the Marlborough medtech company have jointly funded a Boston Scientific product.

The deal lands as Greater Boston’s largest medtech employer recalibrates a flagship cardiovascular program after a cyberattack-hit quarter. Boston Scientific’s headquarters sit in Marlborough, about 30 miles west of Boston, and the company remains a core name in local Boston business news.

What the $455 million buys

Under the collaboration, Blackstone Life Sciences will co-fund Vitalyst development and, in return, can receive regulatory and commercial milestone payments plus royalties on net sales, according to reporting by MedTech Dive and MassDevice. MedTech Dive, citing Boston Scientific’s third-quarter earnings call, said Blackstone can receive up to 2.5 times the amount it provides through milestones, and that Chief Financial Officer Jonathan Monson told analysts the company expects to begin payments to Blackstone in 2030.

Blackstone Life Sciences Global Head Nicholas Galakatos said in the firm’s release that Boston Scientific has “built a leading cardiovascular franchise” and that Vitalyst “has the potential to improve on the efficacy and safety of currently available mechanical circulatory support technologies.” Blackstone said its life-sciences platform manages about $18 billion in assets.

MassDevice reported that Boston Scientific is aiming for a 2030 launch and plans a pivotal trial in 2027 after shifting the lead indication from high-risk percutaneous coronary intervention to AMI-related cardiogenic shock. The company previously completed a 15-patient early feasibility study in high-risk PCI that was published in Circulation: Cardiovascular Interventions; MassDevice summarized that Vitalyst was implanted and removed without reported device malfunctions in all 15 patients, with one nondevice-related cardiac death 24 hours after a successful procedure.

By the numbers

The Boston Report’s reading of the deal terms and market figures reported this week:

• $455 million is the maximum Blackstone Life Sciences commitment disclosed for co-funding Vitalyst development.
• Up to 2.5× that funding can return to Blackstone via regulatory and commercial milestones, per MedTech Dive’s account of the economics, before royalties on sales.
• 2030 is both the year Boston Scientific expects to start paying Blackstone (per the CFO on the Q3 call) and the commercial-launch target reported by MassDevice.
• More than $3 billion is the company’s projected size of the temporary percutaneous ventricular assist device market by 2035, with roughly $1.5 billion of that tied to the acute AMI cardiogenic-shock segment, according to a Boston Scientific email quoted by MedTech Dive.
• Blackstone Life Sciences says it has $18 billion under management; this is its first co-development pact with Boston Scientific, though Fierce Biotech noted a similar 2020 Blackstone collaboration with Medtronic on diabetes R&D.

Why the indication changed

Vitalyst is a temporary mechanical circulatory support pump, in the same broad category as Johnson & Johnson’s Impella devices. Boston Scientific has described a magnetically driven impeller that does not need a purge solution, a design meant to shrink the drive-shaft profile and lower vascular-complication risk, plus catheter and motor features intended to improve positional stability and reduce hemolysis.

CEO Mike Mahoney called Vitalyst “the largest investment we have in the company” at a Bernstein event in May 2025, MedTech Dive reported. After taking the program close to a key study, Boston Scientific chose external co-funding rather than carrying the full late-stage bill alone. The FDA recently cleared a Vitalyst PCI study, but the company told investors it is prioritizing AMI cardiogenic shock because clinical evidence has “called into question the broad use of mechanical circulatory support for high-risk PCI,” Global Chief Medical Officer Kenneth Stein said on the earnings call, according to MedTech Dive. In March, researchers reported that Impella failed to lower major adverse events in complex PCI patients.

Cardiogenic shock after a heart attack remains a high-mortality emergency even with modern care. Blackstone’s release framed Vitalyst as aimed at that unmet need: raising cardiac output and blood flow to the brain and other organs while improving ease of use for physicians.

Local context and prior coverage

The collaboration follows a difficult reporting period for Boston Scientific. In late October the company said third-quarter sales rose only 1.5% after an August cyberattack that disrupted manufacturing and shipping, a hit the company pegged at about $150 million in lost sales. Shares fell on that report; see our earlier story, Boston Scientific Q3 sales rise 1.5% as cyberattack costs $150 million. Offloading a share of Vitalyst’s late-stage cost onto Blackstone reduces cash pressure while the company digests that disruption and a slower 2027 outlook it has already flagged to investors.

For readers tracking Massachusetts medtech and hospital innovation more broadly, related local coverage includes MIT’s magnetic-bead prosthetic sensors and the Boston news business section. Vitalyst itself remains investigational; safety and effectiveness have not been established for commercial use.

Sources

• Blackstone, “Blackstone Life Sciences Announces $455 Million Collaboration…” Nov. 2, 2026
• MedTech Dive, “Boston Scientific, Blackstone agree to $455M deal…,” Nov. 5, 2026
• MassDevice, “Boston Scientific, Blackstone sign $455M deal…,” Nov. 3, 2026
• Fierce Biotech, “Blackstone Life Sciences teams up with Boston Scientific…,” Nov. 4, 2026